HomeCancerLung Officers Share Replace on Section 2 Trial of IDE397 for MTAP-Deletion NSCLC, UC Lung July 11, 2024 66 0 Purposeful Precision Drugs: The New Precision Oncology? August 6, 2026 The Story of Immune Checkpoint Inhibitors and Immunotherapy July 21, 2026 Reflections on Progress at ASCO 2026 June 23, 2026 NCI’s Message and High Priorities June 16, 2026 NCI’s Message and High Priorities May 4, 2026 Officers Share Replace on Section 2 Trial of IDE397 for MTAP-Deletion NSCLC, UC July 11, 2024 Share FacebookTwitterPinterestWhatsApp Previous articleUnderstanding the Position of RNA Methylation in Most cancersNext articleImmunotherapy strategy reveals potential in some folks with metastatic strong tumors Hot Topics Purposeful Precision Drugs: The New Precision Oncology? The Story of Immune Checkpoint Inhibitors and Immunotherapy Reflections on Progress at ASCO 2026 Load more Related Articles Editor - August 6, 2026Purposeful Precision Drugs: The New Precision Oncology? Editor - July 21, 2026The Story of Immune Checkpoint Inhibitors and Immunotherapy Editor - June 23, 2026Reflections on Progress at ASCO 2026 Load more
